New Era Pharmaceutical's Esomeprazole Sodium for Injection has entered the stage of administrative approval

Recently, Shandong New Times Pharmaceutical .

Source: State Food and Drug Administration official website

Esomeprazole is a proton pump inhibitor of gastric parietal cells, which can specifically inhibit H+, K+-ATPases on the secretory microtubules formed by the top membrane of parietal cells and tubular vesicles in the cytoplasm, thereby effectively inhibiting gastric ac.

According to the data from Min.

From the perspective of the competition pattern of manufacturers, the original research manufacturers AstraZeneca, Chia Tai Tianqing Pharmaceutical, and Osaikang are among the top thr.

Sales of esomeprazole sodium for injection at terminals in Chinese public medical institutions in recent years (unit: 10,000 yuan)

Source: Min.

As a commonly used clinical proton pump inhibitor, the market competition of esomeprazole sodium for injection is fier.

Shandong New Era Reviewed Digestive System and Metabolic Drugs

Source: MED0 China Drug Evaluation Database

In the field of digestive system and metabolism, Shandong New Times has 5 varieties that have passed or are deemed to have passed the consistency evaluation, including omeprazole enteric-coated tablets and omeprazole sodium for injection, which are used to treat diseases related to gastric acid secretion of dru.

Omeprazole sodium for injection is planned to be included in the seventh batch of national procureme.

Source: Minet database, the official website of the State Food and Drug Administration, e.